NCT07554742Not yet recruiting
Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and gastric/gastroesophageal junction cancer, analyze the quantitative value of PET parameters in CLDN18.2 expression and their correlation with prognosis, and provide a basis for the precise selection of CLDN18.2-targeted therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 64 (estimated)
- First submitted
- 4 Apr 2026
- Start date
- 15 Apr 2026
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Ruijin Hospital
- NCT number
- NCT07554742
What you commit to
- Study type: Observational
- Planned participants: 64
- From 15 Apr 2026 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with prior Claudin 18.2 targeted therapy.
- Participants with concurrent other active malignancies.
Other illness
- Participants with severe medical conditions that render them unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
Other
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Participants with poor compliance.
Who the study is looking for
- Participants with histopathologically confirmed pancreatic cancer and gastric/gastroesophageal junction cancer with claudin 18.2 expression of any level, including treatment-naive patients with upfront resectable disease, patients with post-operative recurrent disease who are or become resectable following treatment, and patients rendered resectable after neoadjuvant or conversion therapy.
- Signed and dated informed consent form.
- Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- Male or female participants.
- Aged 18-75 years old.
- Good general performance status with an expected overall survival of more than 6 months.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.